Clinical Studies

GutMagnific is not a pharmaceutical drug but a high-quality dietary supplement designed to support gut health.

While GutMagnific is not intended to replace medical treatment, it has been studied in various research collaborations.

We recognize the importance of gut health and its connection to overall well-being. GutMagnific is formulated with a carefully selected multi-strain probiotic blend and is developed for those looking to maintain a balanced gut microbiome.

Through its precisely designed formula, GutMagnific contains a blend of probiotic strains. Maintaining a diverse and balanced gut microbiome is essential for overall digestive health.

Key collaborations include:

• Karolinska Institutet (Stockholm, Sweden):

A double-blind, placebo-controlled clinical study evaluating a multi-strain formulation in individuals with ME/CFS and IBS. Study registered at clinicaltrials.gov – NCT04741841

• Skåne University Hospital (Malmö, Sweden):

A pilot study investigating individuals with IBS following gastroenteritis, previously non-responsive to fecal microbiota transplantation.

• Clostridium difficile Study (Malmö, Sweden):

Evaluation of selected lactic acid bacterial strains in individuals with recurrent Clostridium difficile infection.

• Lund University (Sweden):

A pioneering study launched in 2024 to explore the gut microbiome’s potential role in relation to preeclampsia. Read the press release here.